Our Commercial Business

In 2024, product sales revenue reached €163.3 million for the year ended December 31, 2024 compared to €144.6 million in the same period of 2023, an increase of 13%.

As of 2024, Valneva’s commercial portfolio of traveler vaccines consists of:

• IXIARO^® (also marketed as JESPECT^® in Australia and New Zealand), indicated for the prevention of Japanese encephalitis in travelers and military personnel,
• DUKORAL^®, indicated for the prevention of cholera and, in Canada, Switzerland, New Zealand and Thailand, prevention of diarrhea caused by Enterotoxigenic Escherichia coli, or ETEC, the leading cause of travelers’ diarrhea, and
• IXCHIQ^®, indicated in the U.S., Europe, UK, and Canada for the prevention of disease caused by the chikungunya virus (CHIKV) in individuals 18 years of age and older.
• Additionally, Valneva distributes vaccines for third parties in selected countries where it has a commercial infrastructure but expects to gradually wind down third-party sales to less than 5% of overall product sales by 2026 / 2027, resulting in gross margin improvement.

Valneva has established its own commercial operations in certain travel vaccine markets including the United States, Canada, the United Kingdom, Sweden, France, Austria, Belgium and the Netherlands.

• We manage nearly all our global product sales revenues through our own commercial operations.
• Our commercial teams work continuously to improve service and performance, including embracing digital technology, which allows us to better connect with travelers, physicians, and other health care professionals.
• We put the customer at the heart of our activities and focus on their needs for improved awareness, a deeper understanding of the travel health landscape, and tailor-made services to achieve their objectives.